84,92 €
Deine Einschätzung
Edwards Lifesciences Corp. Aktie
Was spricht für und gegen Edwards Lifesciences Corp. in den nächsten Jahren?
Pro
Kontra
Rendite von Edwards Lifesciences Corp. im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Edwards Lifesciences Corp. | 0,56 % | -0,09 % | 5,96 % | -1,78 % | 22,43 % | -5,48 % | 370,56 % |
QuidelOrtho Corp. | -1,35 % | -5,19 % | -28,43 % | -60,81 % | -56,94 % | -72,35 % | - |
Boston Scientific | 0,00 % | -1,38 % | 2,14 % | 44,30 % | 39,00 % | 93,09 % | 88,51 % |
Waters Corp. | -1,41 % | -1,16 % | -6,80 % | 7,60 % | -12,35 % | -11,77 % | 42,07 % |
Kommentare
News
![Edwards Lifesciences to Host Earnings Conference Call on April 25, 2024:](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd1dOTWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--18ec7f0ddffe02914646ae92f3e6156744ef57fd/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/logo-vertical-transparent.png?locale=de)
Edwards Lifesciences to Host Earnings Conference Call on April 25, 2024
Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2024 after the market closes on Thursday, April 25, 2024, and will host a conference call at
![Edwards Lifesciences to Present at the 44th Annual TD Cowen Healthcare Conference:](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOE9jVmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--35d3dc71bc91537c00371e80355e9bfbbf3e14d0/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/sw_wf.png?locale=de)
Edwards Lifesciences to Present at the 44th Annual TD Cowen Healthcare Conference
Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen Healthcare Conference on Tuesday, March 5, 2024.
Bernard Zovighian, chief executive officer, and
![Edwards Lifesciences Reports Fourth Quarter Results:](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOE9jVmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--35d3dc71bc91537c00371e80355e9bfbbf3e14d0/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/sw_wf.png?locale=de)
Edwards Lifesciences Reports Fourth Quarter Results
Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2023.
Highlights and Outlook
-
Q4 sales grew 14 percent to $1.53 billion; constant currency1